Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma
- PMID: 18577894
Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma
Abstract
Purpose: Despite extensive clinical research, no effective therapy for advanced malignant pleural mesothelioma has been established. In this study, we induced apoptosis in patients with this disease, using intrapleural perfusion hyperthermo-chemotherapy, a new procedure developed in our surgical department. We then measured the tumorcidal effect.
Material and methods: Our study included 6 consecutive patients with malignant pleural mesothelioma (stage III: 5; stage IV: 1). Because of the advanced stage of the disease, none of the patients underwent tumor resection or pleurectomy. All patients, however, received perfusion treatment. Tumor cells collected from pleural effusions pre-and at 0, 24, and 48 h postperfusion were examined using an immunocytochemical stain to determine apoptosis. The percentage of positively stained cells was expressed as the apoptotic index.
Results: Preperfusion, the apoptotic index was 3.8%+/-2.0%, indicating spontaneous apoptosis of untreated tumor cells. Postperfusion, the apoptotic index at 0, 24, and 48 h was 22.8%+/-5.15%, 63.8%+/-8.2%, and 47.8%+/-6.9%, respectively. The patients had a median survival time of 30 months. No patient morbidity was associated with the perfusion treatment.
Conclusion: In patients with malignant pleural mesothelioma, intrapleural perfusion hyperthermo-chemotherapy induced potent apoptosis of tumor cells, increasing immediately postperfusion and peaking at 24 h.
Similar articles
-
Intrapleural hyperthermic perfusion with chemotherapy increases apoptosis in malignant pleuritis.Ann Thorac Surg. 2004 Nov;78(5):1769-72. doi: 10.1016/j.athoracsur.2004.05.025. Ann Thorac Surg. 2004. PMID: 15511471
-
Intrapleural perfusion hyperthermo-chemotherapy for malignant pleural dissemination and effusion.Ann Thorac Surg. 1995 Jan;59(1):127-31. doi: 10.1016/0003-4975(94)00614-D. Ann Thorac Surg. 1995. PMID: 7818311
-
Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.J Clin Oncol. 2005 May 20;23(15):3495-501. doi: 10.1200/JCO.2005.00.802. J Clin Oncol. 2005. PMID: 15908659 Clinical Trial.
-
[Intrapleural perfusion hyperthermo-chemotherapy with cisplatin in patients with malignant pleural mesothelioma].Nihon Geka Gakkai Zasshi. 2009 Nov;110(6):348-52. Nihon Geka Gakkai Zasshi. 2009. PMID: 19999570 Review. Japanese.
-
[Treatment of malignant pleural mesothelioma].Gan To Kagaku Ryoho. 2007 Apr;34(4):520-6. Gan To Kagaku Ryoho. 2007. PMID: 17431335 Review. Japanese.
Cited by
-
Assessment of concentration and penetration depth of cisplatin in human lung tissue after decortication and hyperthermic exposure.Ann Transl Med. 2021 Jun;9(11):953. doi: 10.21037/atm-20-6307. Ann Transl Med. 2021. PMID: 34350268 Free PMC article.
-
[Intraoperative chemotherapy after radical pleurectomy or extrapleural pneumonectomy].Chirurg. 2013 Jun;84(6):492-6. doi: 10.1007/s00104-012-2433-4. Chirurg. 2013. PMID: 23595855 Review. German.
-
Increased efficacy of doxorubicin delivered in multifunctional microparticles for mesothelioma therapy.Int J Cancer. 2011 Jul 1;129(1):233-44. doi: 10.1002/ijc.25666. Epub 2010 Nov 3. Int J Cancer. 2011. PMID: 20830711 Free PMC article.
-
Hyperthermic intrathoracic chemotherapy (HITHOC) in stage IVA thymomas: a narrative review.Mediastinum. 2025 Jun 25;9:16. doi: 10.21037/med-25-8. eCollection 2025. Mediastinum. 2025. PMID: 40666533 Free PMC article. Review.
-
A seven-year disease-free survivor of malignant pleural mesothelioma treated with hyperthermia and chemotherapy: a case report.J Med Case Rep. 2012 Dec 28;6:427. doi: 10.1186/1752-1947-6-427. J Med Case Rep. 2012. PMID: 23272646 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical